Brainstorm Cell Therapeutics Q2 2024 Financial Update

TL;DR

BCLI Q2 assets $79.6M, liabilities $60.5M. Financials filed.

AI Summary

Brainstorm Cell Therapeutics Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $79.6 million and total liabilities of $60.5 million. This filing details their financial position and operational updates for the second quarter of 2024.

Why It Matters

This filing provides investors with a snapshot of Brainstorm Cell Therapeutics' financial health and operational status as of mid-2024, crucial for investment decisions.

Risk Assessment

Risk Level: medium — The company's financial figures indicate a significant portion of assets are liabilities, suggesting potential financial strain or ongoing investment needs.

Key Numbers

• $79.6M — Total Assets (Financial position as of June 30, 2024)
• $60.5M — Total Liabilities (Financial position as of June 30, 2024)

Key Players & Entities

• BRAINSTORM CELL THERAPEUTICS INC. (company) — Filer
• 20240630 (date) — Reporting Period End Date
• $79646942 (dollar_amount) — Total Assets
• $60489208 (dollar_amount) — Total Liabilities

FAQ

Key Financial Figures

• $0.00005 — ange on which registered Common Stock, $0.00005 par value BCLI NASDAQ Stock Market
• $35 million — o meet Nasdaq's minimum market value of $35 million in time for Nasdaq's January 14, 2025 d
• $1 — 82 ) * Represents an amount less than $1. The accompanying notes are an integr

Filing Documents

• bcli-20240630x10q.htm (10-Q) — 1070KB
• bcli-20240630xex4d1.htm (EX-4.1) — 117KB
• bcli-20240630xex10d1.htm (EX-10.1) — 193KB
• bcli-20240630xex10d2.htm (EX-10.2) — 66KB
• bcli-20240630xex10d7.htm (EX-10.7) — 47KB
• bcli-20240630xex10d8.htm (EX-10.8) — 26KB
• bcli-20240630xex10d9.htm (EX-10.9) — 45KB
• bcli-20240630xex10d10.htm (EX-10.10) — 45KB
• bcli-20240630xex31d1.htm (EX-31.1) — 8KB
• bcli-20240630xex31d2.htm (EX-31.2) — 8KB
• bcli-20240630xex32d1.htm (EX-32.1) — 5KB
• bcli-20240630xex32d2.htm (EX-32.2) — 5KB
• 0001410578-24-001400.txt ( ) — 4302KB
• bcli-20240630.xsd (EX-101.SCH) — 29KB
• bcli-20240630_cal.xml (EX-101.CAL) — 27KB
• bcli-20240630_def.xml (EX-101.DEF) — 95KB
• bcli-20240630_lab.xml (EX-101.LAB) — 220KB
• bcli-20240630_pre.xml (EX-101.PRE) — 178KB
• bcli-20240630x10q_htm.xml (XML) — 438KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION 4 Item 1.

Financial Statements

Financial Statements 4 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 41 Item 4.

Controls and Procedures

Controls and Procedures 41

– OTHER INFORMATION

PART II – OTHER INFORMATION 42 Item 1.

Legal Proceedings

Legal Proceedings 42 Item 1A.

Risk Factors

Risk Factors 42 Item 5. Other Information 44 Item 6. Exhibits 45

SIGNATURES

SIGNATURES 47 3 Table of Contents

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS As of June 30, 2024 U.S. DOLLARS IN THOUSANDS (Except share data and exercise prices) (UNAUDITED) 4 Table of Contents BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS As of June 30, 2024 U.S. DOLLARS IN THOUSANDS (Except share data and exercise prices) (UNAUDITED) INDEX Page Interim Condensed Consolidated Balance Sheets 6 Interim Condensed Consolidated Statements of Comprehensive Loss 7 Interim Condensed Statements of Changes in Stockholders' Deficit 8 Interim Condensed Consolidated Statements of Cash Flows 10 Notes to Interim Condensed Consolidated Financial Statements 12 5 Table of Contents BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS U.S. dollars in thousands (Except share data) June 30, December 31, 2024 2023 Unaudited Audited U.S. $ in thousands ASSETS Current Assets: Cash and cash equivalents $ 3,469 $ 1,300 Other accounts receivable 33 51 Prepaid expenses and other current assets (Note 4) 314 548 Total current assets $ 3,816 $ 1,899 Long-Term Assets: Prepaid expenses and other long-term assets $ 20 $ 22 Restricted Cash 179 185 Operating lease right of use asset (Note 5) 1,110 1,416 Property and Equipment, Net 558 686 Total Long-Term Assets $ 1,867 $ 2,309 Total assets $ 5,683 $ 4,208 LIABILITIES AND STOCKHOLDERS' DEFICIT Current Liabilities: Accounts payables $ 5,340 $ 4,954 Accrued expenses 718 1,240 Operating lease liability (Note 5) 566 603 Employees related liability 1,067 1,003 Total current liabilities $ 7,691 $ 7,800 Long-Term Liabilities: Operating lease liability (Note 5) 396 672 Warrants liability (Note 6) 1,123 594 Total long

View Full Filing

View this 10-Q filing on SEC EDGAR